Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Impact of Direct-Acting Antiviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus Nucleic Acid Testing-Positive Transplant Recipients","authors":"Jared Walz,&nbsp;Glen Leverson,&nbsp;Lily Stalter,&nbsp;John Rice,&nbsp;David Al-Adra,&nbsp;Joshua J. Wiegel","doi":"10.1155/jcpt/5727663","DOIUrl":"https://doi.org/10.1155/jcpt/5727663","url":null,"abstract":"<div>\u0000 <p><b>Purpose:</b>​ Direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) such as sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) are effective in treating recipients of organs infected with HCV. The objective of this project is to identify changes in tacrolimus pharmacokinetics throughout DAA therapy in recipients of abdominal transplants from nucleic acid testing-positive (NAT+) donors.</p>\u0000 <p><b>Methods:</b> Adult kidney or liver transplant recipients transplanted between 4/22/2019 and 6/23/2022 were included. Recipients of HCV NAT+ organs were treated with DAAs based on institutional protocol and insurance preference. Recipients of HCV NAT− organs from donors who fit Public Health Service (PHS) risk criteria for HCV transmission were included in the comparator group. Tacrolimus doses and concentrations were collected at DAA initiation and cessation and at the time of sustained virologic response assessment at 12 weeks after treatment completion (SVR12); these time points were matched in the NAT− control group. The primary outcome was difference in concentration-to-dose ratio (C/D) change (ΔC/D) over time between NAT+ and NAT− organ recipients.</p>\u0000 <p><b>Results:</b> At DAA initiation, NAT+ organ recipients required a lower tacrolimus dose to reach goal than NAT− organ recipients (ΔC/D NAT+ = −0.41, ΔC/D NAT− 0.60, <i>p</i> = 0.01); however, a known tacrolimus interaction with fluconazole—administered to liver transplant recipients at high risk for invasive fungal infection (IFI)—represents a significant confounding factor. No differences in average C/D ratio between NAT+ and NAT− organ recipients were identified at any time point.</p>\u0000 <p><b>Conclusion:</b> These results do not support empiric dose adjustments based on donor HCV NAT status or antiviral therapy.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5727663","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Opportunities for Improving Pharmacy Services for People With Disabilities: A Qualitative Study","authors":"Nasser M. Alorfi,&nbsp;Ahmed M. Ashour,&nbsp;Fahad S. Alshehri,&nbsp;Saad M. Wali,&nbsp;Maan H. Harbi,&nbsp;Mohammed M. Aldurdunji,&nbsp;Shaker T. Alsharif,&nbsp;Reem Hasaballah Alhasani,&nbsp;Mohammed S. Alharthi,&nbsp;Nasser M. Aldekhail","doi":"10.1155/jcpt/2437148","DOIUrl":"https://doi.org/10.1155/jcpt/2437148","url":null,"abstract":"&lt;div&gt;\u0000 &lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; People with disabilities face significant barriers to accessing pharmacy services, including physical inaccessibility, communication challenges, and inadequate pharmacist training. These barriers often result in poor healthcare outcomes, which lead to a decline in the provided services.&lt;/p&gt;\u0000 &lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore hospital pharmacists’ experiences, challenges, and suggestions for improving pharmacy services for individuals with disabilities in Saudi Arabia.&lt;/p&gt;\u0000 &lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; A qualitative study was conducted using semistructured interviews with fifteen hospital pharmacists selected through purposive sampling. Participants had to have had at least 5 years of experience and direct interaction with disabled patients. Data were transcribed &lt;i&gt;verbatim&lt;/i&gt; and analyzed using thematic analysis to identify recurring themes and insights. An inductive thematic analysis approach was employed.&lt;/p&gt;\u0000 &lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; The analysis revealed five key themes: (1) physical inaccessibility of pharmacy infrastructure, (2) communication barriers, (3) training needs, (4) the role of assistive technologies, and (5) proposed service improvements. Technology was recognized as a facilitator, with tools such as Braille medication labels, automated dispensing systems, and mobile health applications identified as potential solutions. Participants also proposed structural modifications, mandatory training programs, and dedicated service pathways to address identified challenges. These findings highlight the importance of a comprehensive approach that integrates infrastructure redesign, targeted training, technological solutions, and inclusive healthcare policies.&lt;/p&gt;\u0000 &lt;p&gt;&lt;b&gt;Conclusion:&lt;/b&gt; Improving pharmacy services for individuals with disabilities requires structural, educational, and technological interventions to enhance accessibility, communication, and service delivery.&lt;/p&gt;\u0000 &lt;p&gt;&lt;b&gt;Implications for Research and Practice:&lt;/b&gt; The findings of this study provide valuable insights into the barriers faced by individuals with disabilities when accessing pharmacy services and offer actionable recommendations for improvement. From a practical perspective, healthcare institutions should prioritize mandatory disability-awareness and communication training programs for pharmacists, focusing on skills such as sign language, assistive technology use, and inclusive communication strategies. Structural modifications to pharmacy infrastructure, including lowered counters, wider aisles, and accessible shelving, are essential to ensure physical accessibility. In addition, the integration of assistive technologies, such as Braille labels, voice-assisted mobile apps, and automated dispensing systems, can help address communication gaps and improve medication adherence. Dedicated service pathways for patients with disabilities can further enhance privacy, reduce waiting times, and","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2437148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144331918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Unidirectional Buccal Patches Loaded With Lidocaine and Dexmedetomidine Ameliorate Injection Pain in Dental Procedures? A Double-Blinded Randomized Controlled Trial","authors":"Elham Panahandeh,&nbsp;Erfaneh Ghassami,&nbsp;Milad Etemadi Sh,&nbsp;Sarah Seyedyousefi,&nbsp;Jaleh Varshosaz","doi":"10.1155/jcpt/9930530","DOIUrl":"https://doi.org/10.1155/jcpt/9930530","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Dental anxiety is a critical issue in dentistry. Buccal patches, a noninvasive drug delivery method, can potentially alleviate anxiety and pain during dental procedures. This study aimed to develop a three-layered buccal drug delivery system containing lidocaine or lidocaine–dexmedetomidine for improved pain management in dentistry.</p>\u0000 <p><b>Methods:</b> Three-layered patches were made using ethyl cellulose, eudragit, and Carbopol, incorporating either lidocaine or a combination of lidocaine–dexmedetomidine. Forty participants were included: Both groups received placebo patches on one side of jaw and received their relevant drug patch of lidocaine or lidocaine–dexmedetomidine on the other side. Pain levels were assessed.</p>\u0000 <p><b>Results:</b> The patches were 2-3 mm thick with a pH of 3.5–4.5. Lidocaine release efficiency was 41.69 ± 13.10%, and the combination patches showed 47.17 ± 5.10% for lidocaine and 74.71 ± 6.41% for dexmedetomidine. Release time for lidocaine and the combination patch was 25 and 15 min, respectively, with dexmedetomidine fully released within 3 min. The lidocaine–dexmedetomidine group reported significantly lower pain scores (2.1 ± 0.3) compared to the lidocaine group (4.3 ± 0.4) and placebo (6.8 ± 0.5). The onset and duration of analgesia was faster in the combination group versus the lidocaine group (5.2 ± 0.5 vs. 8.7 ± 0.6 min and 45 ± 5 vs. 30 ± 4 min, respectively).</p>\u0000 <p><b>Conclusion:</b> Buccal patches, especially lidocaine–dexmedetomidine patches, significantly reduce pain and improve patient comfort. These patches offer a promising noninvasive alternative for pain management with enhanced efficacy and patient compliance. Further research is needed to optimize these patches for broader clinical applications.</p>\u0000 <p><b>Trial Registration:</b> Iranian Clinical Trials Registration Center: IRCT20210118050067N2</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9930530","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Rifampicin on the Pharmacokinetics of the Glucokinase Activator Globalagliatin: A Single-Center, Open-Label, Fixed-Sequence Investigation in Healthy Chinese Volunteers","authors":"Yaqin Wang,&nbsp;Ya Liu,&nbsp;Maodi Xu,&nbsp;Minhui Wang,&nbsp;Xiaohu Wang,&nbsp;Weijin Liu,&nbsp;Cuilian Jiang,&nbsp;Lin Tan,&nbsp;Suoshuan Liu,&nbsp;Hua Sun,&nbsp;Haitang Xie","doi":"10.1155/jcpt/5690902","DOIUrl":"https://doi.org/10.1155/jcpt/5690902","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> The orally bioavailable glucokinase activator, globalagliatin, is used to improve glucose homeostasis. Its metabolism is primarily dependent on cytochrome P450 (CYP) 3A4. Here, the influence of rifampicin, a potent inducer of CYP3A4 and CYP2C19 inducer, moderate inducer of CYP1A2, CYP2B6, CYP2C8, and CYP2C9, and inhibitor of P-gp, on the pharmacokinetics of globalagliatin, were investigated in healthy Chinese subjects.</p>\u0000 <p><b>Methods:</b> This single-center, open-label, one-sequence investigation was performed over 22 days in 24 healthy Chinese volunteers. The volunteers were given single oral doses of 80 mg of globalagliatin on Days 1 and 15 on an empty stomach, while rifampicin 600 mg was given orally once a day from Days 8–21 before breakfast. Blood samples were collected at 0 h (1 h before globalagliatin administration on Days 1 and 15) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, and 168 h after dosing to monitor the globalagliatin pharmacokinetic parameters. Blood samples on Day 8 were collected before rifampicin administration. The plasma levels of globalagliatin were assessed using LC-MS/MS. Pharmacokinetic parameters were calculated using Phoenix WinNonlin Version 8.3.3 and analyzed with SAS Version 9.4. Continuous monitoring was performed to assess drug safety and tolerance.</p>\u0000 <p><b>Results:</b> Analysis of the effect of rifampicin on globalagliatin pharmacokinetics in 24 healthy participants showed that with rifampicin, the C_max of globalagliatin decreased by 88.9%, while the AUC_0–t and AUC_0–∞ values were reduced by 97.0% and 96.4%, respectively. The geometric mean ratios of globalagliatin C_max, AUC_0–t, and AUC_0–∞ and their 90% CI values were 11.09% (90% CI:9.40–13.10%), 2.96% (90% CI:2.59–3.39%), and 3.60% (90% CI:3.20–4.04%), respectively. The mean elimination half-life was reduced by 27.91 h, while T_max was prolonged by 3.52 h. Six treatment-related adverse events were reported by five subjects (20.8%), with all being of Grade 1 severity.</p>\u0000 <p><b>Conclusions:</b> Cotreatment with rifampicin significantly reduces the plasma levels of globalagliatin. The safety and tolerability of globalagliatin, both as monotherapy and in combination with rifampicin, were good in healthy Chinese volunteers.</p>\u0000 <p><b>Trial Registration:</b> Chinese Clinical Trial Register: CTR20210959</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5690902","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Area Under the Concentration–Time Curve–Based Vancomycin Dosing on Efficacy and Safety in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia","authors":"Amy T. Chang,&nbsp;Christie Davis,&nbsp;Megan Cheatham,&nbsp;Kerri Degenkolb,&nbsp;Christopher Geik,&nbsp;Michael B. Kays,&nbsp;Sharon M. Erdman","doi":"10.1155/jcpt/5147445","DOIUrl":"https://doi.org/10.1155/jcpt/5147445","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The optimal strategy for dosing and monitoring vancomycin continues to evolve. A vancomycin 24-h steady-state area under the concentration–time curve/minimum inhibitory concentration (AUC/MIC) of ≥ 400 has been associated with positive clinical outcomes, while an AUC/MIC &gt; 600–700 has been associated with increased risk of nephrotoxicity. The 2009 vancomycin dosing guidelines recommended target trough concentrations between 10–20 mcg/mL depending on infection; however, recent pharmacokinetic data suggest that most patients can achieve target AUC/MIC with trough concentrations &lt; 15 mcg/mL. While existing literature has demonstrated reduced nephrotoxicity with AUC-guided dosing (AGD), there are limited data evaluating efficacy and other clinical outcomes. Therefore, this study compared the clinical efficacy of vancomycin using trough-guided dosing (TGD) versus AGD in patients with confirmed methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteremia.</p>\u0000 <p><b>Methods:</b> This was a retrospective, observational, quasiexperimental study of adult patients who received vancomycin for treatment of MRSA bacteremia. Patients with central nervous system infections, weighing &gt; 200 kg, with acute kidney injury, or receiving hemodialysis/continuous renal replacement therapy were excluded. The primary outcome was microbiological success defined as negative blood cultures within 7 days of vancomycin initiation. Secondary outcomes included achievement of therapeutic target concentrations and incidence of nephrotoxicity.</p>\u0000 <p><b>Results:</b> Microbiological success was achieved in 52/55 (95%) patients with TGD versus 50/51 (98%) patients with AGD (<i>p</i> = 0.619). In the TGD group, 24/55 (44%) patients achieved therapeutic target concentrations within 48 h of initiation of vancomycin compared to 24/51 (47%) patients in the AGD group (<i>p</i> = 0.723). The median hospital length of stay was longer in the TGD group compared to the AGD group (16 days, IQR 11–27 days versus 13 days, IQR 9–24 days, respectively, <i>p</i> = 0.260). Nephrotoxicity occurred in 7/55 (13%) TGD patients versus 5/51 (10%) AGD patients during vancomycin therapy (<i>p</i> = 0.763).</p>\u0000 <p><b>Conclusions:</b> AGD was similar to TGD at achieving microbiological success in patients with MRSA bacteremia and may lead to shorter lengths of hospital stay and lower rates of nephrotoxicity.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5147445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polypharmacy and Potential Drug–Drug Interactions in Patients With Atrial Fibrillation","authors":"Ying Bai,&nbsp;Jianqi Wang,&nbsp;Guangyao Li,&nbsp;Zhen Zhou","doi":"10.1155/jcpt/6632271","DOIUrl":"https://doi.org/10.1155/jcpt/6632271","url":null,"abstract":"<div>\u0000 <p><b>What is Known and Objective:</b> The use of multiple medications, or polypharmacy, is associated with an elevated risk of potential drug–drug interactions (pDDIs), consequently heightening the probability of adverse drug reactions. Currently, there is a dearth of data regarding pDDIs in Chinese patients with atrial fibrillation (AF) within real-world scenarios. This study is designed to investigate the existing state of polypharmacy and pDDIs in Chinese AF patients and to analyze the factors influencing pDDIs.</p>\u0000 <p><b>Methods:</b> This was a single-center retrospective investigation conducted at a tertiary hospital in China. Polypharmacy and pDDIs were examined based on the medications prescribed at the time of discharge. The pDDIs were assessed using the Lexi-Interact database and classified into Types A, B, C, D, and X.</p>\u0000 <p><b>Results and Discussion:</b> The study encompassed 802 AF patients. The median age was 73 years (ranging from 64 to 80). The most (72.7%) were 65 years or older, and 53.9% were male. The incidence rates of polypharmacy and excessive polypharmacy were 74.8% and 29.8%, respectively. At discharge, 69.0% of patients had at least one clinically relevant pDDI. There were 1820 (84.2%), 261 (12.1%), and 81 (3.7%) interactions categorized as Types C, D, and X, respectively. The most prevalent Type C interaction was the combined use of antihypertensive medications. Among Type D interactions, the most common was the combination of anticoagulants and antiplatelet drugs. The most frequent Type X interaction involved drugs that augmented the hyperkalemic effect. Through multivariate analysis, advanced age (<i>p</i> = 0.008) and a greater number of medications (<i>p</i> &lt; 0.001) were significant predictors of pDDIs.</p>\u0000 <p><b>What is New and Conclusions:</b> Polypharmacy and pDDIs are widespread among AF patients. Advanced age and an increased number of drugs were determined to be predictive factors for pDDIs. The risk of DDIs can be reduced by decreasing the number of medications or opting for alternative drugs.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6632271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wenjing Zhitong Decoction Alleviates Primary Dysmenorrhea Mediated by Pain Sensitization Via the ERα-BDNF Signaling Pathway","authors":"Yajie Qin,&nbsp;Xiaotian Yang,&nbsp;Xingran Tang,&nbsp;Huijin Zhao,&nbsp;Huifang Zhou","doi":"10.1155/jcpt/5516416","DOIUrl":"https://doi.org/10.1155/jcpt/5516416","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Wen-Jing-Zhi-Tong decoction (WJZTD) is a traditional Chinese medicine herbal decoction that has demonstrated clinical efficacy in treating primary dysmenorrhea (PDM) over decades. However, the underlying therapeutic mechanism of WJZTD requires further clarification.</p>\u0000 <p><b>Objective:</b> This study aims to explore and elucidate the therapeutic mechanism of WJZTD in treating PDM through metabolomics, integrated network pharmacology, as well as in vitro and in vivo experiments.</p>\u0000 <p><b>Methods:</b> A PDM rat model was established by estradiol benzoate and oxytocin for 3 consecutive estrous cycles, and then WJZTD treatment was administered for 3 consecutive estrous cycles. To evaluate the therapeutic effect of WJZTD on PDM, behavioral tests, histological analysis, and evaluation of serum prostaglandins (PGs) were performed. Moreover, immunofluorescence and Western blot analysis were carried out in dorsal root ganglion (DRG) tissues to explore the role of WJZTD in reducing pain sensitivity. Metabolomics and integrated pharmacology were utilized to identify potential bioactive targets, which were then validated through in vitro experiments.</p>\u0000 <p><b>Results:</b> WJZTD significantly reduces pain sensitivity in PDM rats, treating the condition effectively by decreasing brain-derived neurotrophic factor (BDNF) protein expression, c-Fos-positive neurons in DRG, and serum prostaglandin PGF2α (PGF2α) levels. A nontargeted metabolic analysis identified 11 differential metabolites, suggesting ESR1 (estrogen receptor α, ERα) as a potential target. In vitro experiments confirmed WJZTD’s efficacy in treating PDM through regulating the ERα/BDNF signaling pathway.</p>\u0000 <p><b>Conclusion:</b> WJZTD decreases the excitability of DRG neurons in rats with PDM through the ERα/BDNF pathway, which enhances pain sensitization and contributes to reducing dysmenorrhea.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5516416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linezolid-Induced Lactic Acidosis: Avoiding Concomitant Use With Metformin and Monitoring Linezolid Trough Concentration","authors":"Yao-Jie Chen,&nbsp;Jing Fu,&nbsp;Jun-Hui Yu,&nbsp;Li-Wen Zhang,&nbsp;Chuang Chen,&nbsp;Hai-Na Zhang,&nbsp;Xu-Ben Yu,&nbsp;Guan-Yang Lin,&nbsp;Xiu-Hua Zhang","doi":"10.1155/jcpt/4929946","DOIUrl":"https://doi.org/10.1155/jcpt/4929946","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> Serum lactic acidosis has been reported as a serious adverse effect associated with linezolid. This study aims to explore the risk factors of linezolid-induced lactic acidosis.</p>\u0000 <p><b>Methods:</b> Patients admitted to a 3600-bed university hospital, who received linezolid treatment and had at least one steady-state concentration of linezolid, were retrospectively reviewed to analyze the incidence of linezolid-induced lactic acidosis. Meanwhile, univariate and multivariate logistic regression analyses were conducted to determine the risk factors of lactic acidosis.</p>\u0000 <p><b>Results:</b> A total of 95 adult patients were included in the study. 18.95% (18 out of 95) of patients developed lactic acidosis during linezolid treatment. Importantly, patients who concurrently used linezolid and metformin had a high risk of developing lactic acidosis (90.9%, 10 out of 11). After excluding these patients from the original database, 9.52% (8 out of the 84) of the patients developed lactic acidosis. In the population not receiving concurrent metformin treatment, univariate analysis showed that patients who developed lactic acidosis had higher linezolid <i>C</i>_min and serum creatinine levels or lower creatinine clearance, and multivariate analysis showed that <i>C</i>_min (OR: 1.114; 95% CI: 1.012–1.226; <i>p</i> = 0.027) was an independent risk factor for lactic acidosis.</p>\u0000 <p><b>Conclusion:</b> The concurrent use of linezolid and metformin raises the risk of lactic acidosis. Therapeutic drug monitoring of linezolid based on <i>C</i>_min is recommended for decreasing the risk of lactic acidosis during linezolid treatment.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/4929946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Biological or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta-Analysis of Randomized Controlled Trials","authors":"Siming Gao,&nbsp;Hui Song","doi":"10.1155/jcpt/6541156","DOIUrl":"https://doi.org/10.1155/jcpt/6541156","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> Many biological or targeted synthetic disease-modifying anti-rheumatic drugs (b/ts DMARDs) are used in the treatment of psoriatic arthritis (PsA) during recent years, but there are few head-to-head studies that directly compare these drugs to evaluate and compare the relative efficacy of these treatments at week 24. The aim of this study is to conduct a comprehensive comparison of all clinically used bDMARDs or tsDMARDs for PSA using a network meta-analysis to evaluate relative efficacy of these drugs, which is evaluated by ACR20, ACR50, ACR70, PASI75, and PASI90.</p>\u0000 <p><b>Methods:</b> All randomized controlled trials of these treatments are searched in PubMed, Web of Science, and Embase, and data are extracted from the included articles, and network meta-analysis is performed using the Stata 13 software.</p>\u0000 <p><b>Results:</b> secukinumab 300 mg is the top-ranked treatment for ACR20 and PASI90, infliximab 5 mg/kg is the top-ranked treatment for ACR50, and adalimumab 40 mg is the top-ranked treatment for ACR70 and PASI75.</p>\u0000 <p><b>Conclusions:</b> Tumor necrosis factor-α inhibitors and interleukin 17A inhibitors are the top-ranked treatments for arthritis and skin responses of active PsA.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6541156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Therapeutic Effect of Quercetin in Asthma and Pulmonary Fibrosis Overlap Syndrome Post-COVID-19","authors":"Baolan Wang,&nbsp;Zhe Zhang,&nbsp;Yi Wang,&nbsp;Rong Zhu,&nbsp;Xiuqin Zhang","doi":"10.1155/jcpt/5548573","DOIUrl":"https://doi.org/10.1155/jcpt/5548573","url":null,"abstract":"<div>\u0000 <p><b>Backgrounds:</b> Quercetin has potentially beneficial therapeutic effects for several chronic, inflammatory disorders of the airways. Thus, we explore the therapeutic value and mechanism of quercetin in the treatment of asthma and pulmonary fibrosis overlap syndrome after COVID-19.</p>\u0000 <p><b>Methods:</b> The potential targets and molecular mechanisms of quercetin for the treatment of overlap syndrome were predicted using a network pharmacology method. The binding mechanism between the core potential compounds and their targets was predicted using molecular docking with AutoDock Vina. An asthma model induced by ovalbumin was built to evaluate the effect of quercetin on asthma.</p>\u0000 <p><b>Results:</b> 55 common targets and eight key genes between the overlap syndrome and quercetin were obtained for further study. Most of the interested target genes were mainly focused on inflammation-related signaling pathways. Via molecular docking, quercetin showed a high degree of affinity for TNF, IL-6, and MMP9. In addition, quercetin improved asthma symptoms, inflammatory response, and pulmonary fibrosis.</p>\u0000 <p><b>Conclusion:</b> This study, which examined the use of quercetin for the treatment of the overlap syndrome of asthma and pulmonary fibrosis following COVID-19 from the aspect of network pharmacology, might serve as a useful guidepost for future studies and clinical applications.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5548573","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}